Our Members

As a member-focused Association, our members are at the heart of everything we do at the PRI.

In principle any organization (public or private) is eligible to join the Association and become part of Europe’s growing microbiome-based medicinal product ecosystem.

Find out more about the different ways you and your organization can get involved with the PRI’s activities.

  • Microbiome Regulatory Science Support Work
  • Pre-competitive Task Groups
  • Year-round networking and project-related communication support

More than 100 PRI Members from 24 countries represent nearly every point along the microbiome science and development continuum, from fundamental research groups all the way to commercial manufacturing partners and pharmaceutical companies.

DestinyPharma

DestinyPharma

Camilla Costa

Director Regulatory Affairs

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

 

DNA Genotek Inc.

DNA Genotek Inc.

Héloïse Breton

Sr. Product Manager, Microbiome & Metabolomics

DNA Genotek, a subsidiary of OraSure Technologies, Inc., develops products that optimize ease of collection and provide superior samples and proven performance for those requiring high-quality biological samples for nucleic acid and metabolomic testing.

 

Don Whitley Scientific Limited

Don Whitley Scientific Limited

Andrew Pridmore

Head of Science

GLP compliant contract microbiological laboratory services, specializing in antibiotic susceptibility testing and cultivation of highly fastidious bacterial strains.

 

DTU Biosustain

DTU Biosustain

Jen Kindtler

VP Research and Development

 

 

Eagle Genomics

Eagle Genomics

Christian Roghi

Director of Microbiome Solutions

Eagle Genomics applies network science to biology. We are revealing the impact of the microbiome on humans, animals and the environment to secure a sustainable future for our food, water, soil and the health of our planet.

 

Eligo Bioscience

Eligo Bioscience

Aurelie Grienenberger

Chief Buisness Officer

Eligo is pioneering microbiome gene therapy, a proprietary platform technology that has the potential to precisely modify the microbiome composition and function.

 

EnteroBiotix

EnteroBiotix

James McIlroy

Founder & CEO

Our vision is to transform the standard of care for patients suffering from substantial unmet clinical needs through microbiome modulating therapeutics and in doing so, create a sustainable pharmaceutical company.

 

ENTEROSYS

ENTEROSYS

Anne Abot

CSO

ENTEROSYS specializes in the preclinical evaluation of compounds of interest on the digestive sphere, the enteric nervous system and the communication between the intestine and peripheral organs.